IL135947A0 - Human blood bacterium - Google Patents

Human blood bacterium

Info

Publication number
IL135947A0
IL135947A0 IL13594798A IL13594798A IL135947A0 IL 135947 A0 IL135947 A0 IL 135947A0 IL 13594798 A IL13594798 A IL 13594798A IL 13594798 A IL13594798 A IL 13594798A IL 135947 A0 IL135947 A0 IL 135947A0
Authority
IL
Israel
Prior art keywords
human blood
blood bacterium
bacterium
human
blood
Prior art date
Application number
IL13594798A
Other languages
English (en)
Original Assignee
Pathobiotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathobiotek Inc filed Critical Pathobiotek Inc
Publication of IL135947A0 publication Critical patent/IL135947A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13594798A 1997-11-06 1998-11-06 Human blood bacterium IL135947A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6447297P 1997-11-06 1997-11-06
PCT/US1998/023674 WO1999024613A1 (en) 1997-11-06 1998-11-06 Human blood bacterium

Publications (1)

Publication Number Publication Date
IL135947A0 true IL135947A0 (en) 2001-05-20

Family

ID=22056229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13594798A IL135947A0 (en) 1997-11-06 1998-11-06 Human blood bacterium

Country Status (7)

Country Link
US (2) US6255467B1 (xx)
EP (1) EP1029080A1 (xx)
JP (1) JP2002502583A (xx)
AU (1) AU761246B2 (xx)
CA (1) CA2308779A1 (xx)
IL (1) IL135947A0 (xx)
WO (1) WO1999024613A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2800747B1 (fr) * 1999-11-10 2003-05-30 Inst Rech Developpement Ird Nouvelles bacteries symbiotiques et leurs applications
US7235397B1 (en) 2000-04-14 2007-06-26 Gensys, Inc. Methods and compositions for culturing spirochete and treating spirochetal diseases
EP1474151A4 (en) * 2002-01-17 2010-03-03 R E D Lab N V METHODS OF TREATING CHRONIC IMMUNE DISEASE
DE10244456A1 (de) * 2002-09-24 2004-04-15 Hain Lifescience Gmbh Verfahren zum Nachweis und Differenzierung von Bakterien
AU2004214938B2 (en) * 2003-02-26 2008-11-06 Johns Hopkins University Glutamate transport modulatory compounds and methods
CA2523693A1 (en) * 2003-04-10 2004-10-28 Salisbury University Bacteriophage for lysis of methylobacterium and compositions and uses thereof
CN101052468B (zh) * 2004-09-09 2012-02-01 居里研究所 采用共线电场的微流控装置
US9474744B2 (en) 2011-09-21 2016-10-25 Stem Cell Medicine Ltd. Beta-lactam compounds for treating diabetes
EP2741748B1 (en) 2011-09-21 2018-09-12 Stem Cell Medicine Ltd. Beta-lactam compounds for enhancing t cell-mediated immune responses
US9758773B2 (en) 2014-02-14 2017-09-12 Agilent Technologies, Inc. Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood
EP3351642B1 (en) 2014-06-13 2019-09-11 Q-Linea AB Method for detecting and characterising a microorganism
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
GB201507026D0 (en) 2015-04-24 2015-06-10 Linea Ab Q Medical sample transportation container
GB2554767A (en) 2016-04-21 2018-04-11 Q Linea Ab Detecting and characterising a microorganism
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761370A (en) * 1986-06-16 1988-08-02 Cleveland Clinic Foundation Method for determining the presence of bacteria in body fluid specimens containing bacterial inhibitors
US5635348A (en) * 1990-10-05 1997-06-03 Hoffmann-La Roche Inc. Method and probes for identifying bacteria found in blood

Also Published As

Publication number Publication date
CA2308779A1 (en) 1999-05-20
JP2002502583A (ja) 2002-01-29
EP1029080A1 (en) 2000-08-23
US20020155519A1 (en) 2002-10-24
US6255467B1 (en) 2001-07-03
AU761246B2 (en) 2003-05-29
AU1451999A (en) 1999-05-31
WO1999024613A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
PL328822A1 (en) Human bikinine
ZA978450B (en) Medical treatment
GB9617502D0 (en) Medical devices
IL135947A0 (en) Human blood bacterium
GB9610682D0 (en) Medical devices
EP1012262A4 (en) HFLP PROTEIN HFLP
HUP9901448A3 (en) Novel medical use
GB2303303B (en) Medical treatment
GB9521725D0 (en) Medical treatment
GB9700875D0 (en) Medical devices
GB9509016D0 (en) Tissue entrapment
EP0797592A4 (en) HUMAN STANNIOCALCIN ALPHA
EP1140120A4 (en) BRAINIAC-5 HUMANS
EP1077258A4 (en) HUMAN HRPI GENE
GB9526264D0 (en) Medical treatment
GB9617550D0 (en) Medical ice-pack
ZA947865B (en) Human glactokinase
GB9601042D0 (en) Medical use
GB9710544D0 (en) Medical treatment
EP0795006A4 (en) HUMAN MuT2
TW357555U (en) Patient trousures
GB9603437D0 (en) Medical aid
GB9602728D0 (en) Medical treatment
GB9626859D0 (en) Medical treatment
GB9612330D0 (en) Medical treatment